USPTO serial 88048381
CYTOSEN THERAPEUTICS
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- RATCLIFFE, ROBERT L
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CYTOSEN THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
KIADIS PHARMA INTELLECTUAL PROPERTY B.V.
AMSTERDAM, NL
Other trademarks owned by KIADIS PHARMA INTELLECTUAL PROPERTY B.V.
Winter Springs, FL
Winter Springs, FL
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Matthew J. Smith
MATTHEW J. SMITH POLSINELLI PC100 SOUTH FOURTH STREETSUITE 1000ST. LOUIS, MO 63102Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of immuno oncological disorders, cancer, diabetes, respiratory, heart, neurological and auto immune disorders; stem cells for medical purposes; living cells for medical use; biological preparations for the treatment of cancer; therapeutic pharmaceuticals utilizing neural crest cells for use in the treatment of cancer, autoimmune disease and infectious diseases; Cell preparations, cellular vaccines and cellular biologics for the treatment of cancer and infectious diseases by autologous cell-based immunotherapy | ACTIVE | — |
| 042 | Scientific and technological services, namely, scientific research, design, analysis and testing in the field of cancer evolution and new cancer therapies using natural killer cells; industrial research in the field of new pharmaceutical products and new cancer therapies; medical and veterinary research services in the nature of the manipulation of cells within a laboratory or research facility to enable natural killer cells to be used for medical or therapeutic purposes; scientific research in the development of new cancer therapies; scientific research in human and animal cell therapy; scientific research into preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services; Conducting research and clinical trials for others relating to the use and the engineering of natural killer cells and cancer treatment and therapy; medical and scientific research in the field of cancer treatment and diagnosis; data collection for others for research purposes, namely, the collection, testing and research of patient molecular and genomic data; collection and preservation of human and animal DNA for research purposes | ACTIVE | — |
| 044 | Medical testing for diagnostic or treatment purposes in the field of cancer research; medical diagnostic testing, monitoring and reporting services; medical evaluation of immuno oncological disorders, cancer, diabetes, respiratory, heart, neurological and auto immune disorders; medical monitoring services; medical diagnostic, prognostic and theranostic screening and testing services; collection and preservation of dna for medical purposes; consulting services in the nature of providing medical information; consulting services in the field of healthcare and cancer diagnoses; providing a website featuring health and healthcare information related to cancer, testing and screening; genetic testing for medical purposes; providing information in the field of cancer prevention, screening, diagnosis and treatment for medical diagnostic and treatment purposes; providing genetics assessments in the nature of genetic counseling; genetic testing for medical diagnostic purposes; genomic testing for medical diagnostic purposes; Gene analysis and sequencing and DNA analysis and sequencing for medical diagnostic purposes and veterinary diagnostics purposes; gene analysis and sequencing and DNA analysis and sequencing for use in cancer diagnosis and treatment; providing a website featuring health and healthcare information related to cancer research | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by KIADIS PHARMA INTELLECTUAL PROPERTY B.V.
- Other trademarks owned by CytoSen Therapeutics, Inc.
- Other trademarks owned by CytoSen Therapeutics, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named CYTOSEN THERAPEUTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 23, 2020 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jul 6, 2020 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 6, 2020 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 6, 2019 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 4, 2019 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 4, 2019 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 4, 2019 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 4, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 9, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 9, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 20, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 15, 2019 | APET | ASSIGNED TO PETITION STAFF | — |
| Mar 5, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 5, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 5, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 5, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 5, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 4, 2019 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Feb 26, 2019 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Feb 13, 2019 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 11, 2019 | ALIE | ASSIGNED TO LIE | — |
| Jan 28, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 23, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 22, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 22, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 20, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 20, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 20, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 8, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 27, 2018 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jul 26, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 26, 2018 | NWAP | NEW APPLICATION ENTERED | — |